|
|
|
|
| LEADER |
01907nmm a2200433 u 4500 |
| 001 |
EB001957550 |
| 003 |
EBX01000000000000001120452 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
210211 ||| eng |
| 100 |
1 |
|
|a Montefiori, David
|
| 245 |
0 |
0 |
|a SARS-CoV-2 mutations
|h Elektronische Ressource
|b phenotypes and implications for vaccine development
|c an interview with David Montefiori
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2021, 2021
|
| 300 |
|
|
|a 1 streaming audio file (10 min.))
|
| 505 |
0 |
|
|a Currently known SARS-CoV-2 strains -- Likelihood of mutating into a more lethal form of SARS-CoV-2 -- Spike proteins and their role in viral entry into human cells -- SARS-CoV-2 is mutating into a more transmissible or infectious form -- Implications of new SARS-CoV-2 variants on public health and vaccine development -- Importance of continuing genetic surveillance of the virus
|
| 653 |
|
|
|a COVID-19 Vaccines
|
| 653 |
|
|
|a SARS-CoV-2 / genetics
|
| 653 |
|
|
|a Spike Glycoprotein, Coronavirus
|
| 653 |
|
|
|a Drug Resistance, Viral
|
| 653 |
|
|
|a Pandemics
|
| 653 |
|
|
|a COVID-19 (Disease) / Genetics
|
| 653 |
|
|
|a Coronaviruses
|
| 653 |
|
|
|a Genetic Variation
|
| 653 |
|
|
|a Vaccines / Development
|
| 653 |
|
|
|a COVID-19 (Disease) / Research
|
| 653 |
|
|
|a COVID-19 / virology
|
| 653 |
|
|
|a Coronavirus Infections
|
| 653 |
|
|
|a SARS-CoV-2 / pathogenicity
|
| 653 |
|
|
|a COVID-19 / physiopathology
|
| 653 |
|
|
|a Mutation
|
| 653 |
|
|
|a COVID-19 Pandemic, 2020-
|
| 653 |
|
|
|a Epidemiological Monitoring
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Research and clinical interviews
|
| 500 |
|
|
|a Audio interview. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/4515
|x Verlag
|z Streaming video file
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1060
|3 Series
|
| 082 |
0 |
|
|a 570
|